NYSE:BMY

Bristol-Myers Squibb Stock Forecast, Price & News

$78.53

-1.45 (-1.81%)

(As of 06/28/2022 03:04 PM ET)

Add

Compare

Today's Range: $78.49
▼
$80.39
50-Day Range: $72.62
▼
$79.98
52-Week Range: $53.22
▼
$80.59

Volume: 344,872 shs
Average Volume: 13.19 million shs
Market Capitalization: $167.20 billion

P/E Ratio: 27.85
Dividend Yield: 2.74%
Price Target: $74.27

30 days | 90 days | 365 days | Advanced Chart

Receive BMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bristol-Myers Squibb and its competitors with MarketBeat's FREE daily newsletter.

BMY Stock Forecast (MarketRank)

Overall MarketRank^™

2.77 out of 5 stars

Medical Sector

44th out of 1,436 stocks

Pharmaceutical Preparations Industry

15th out of 687 stocks

2.2 Analyst's Opinion

Consensus Rating
Bristol-Myers Squibb has received a consensus rating of Hold. The company's average rating score is 2.45, and is based on 6 buy ratings, 4 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $74.27, Bristol-Myers Squibb has a forecasted downside of 5.6% from its current price of $78.72.
Amount of Analyst Coverage
Bristol-Myers Squibb has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

4.5 Community Rank

Outperform Votes
Bristol-Myers Squibb has received 1,048 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Bristol-Myers Squibb has received 484 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Bristol-Myers Squibb has received 68.41% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Bristol-Myers Squibb and other stocks. Vote “Outperform” if you believe BMY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BMY will underperform the S&P 500 over the long term. You may vote once every thirty days.

3.3 Dividend Strength

Dividend Yield
Bristol-Myers Squibb pays a meaningful dividend of 2.74%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Bristol-Myers Squibb has been increasing its dividend for 16 years.
Dividend Coverage
The dividend payout ratio of Bristol-Myers Squibb is 76.60%. Payout ratios above 75% are not desirable because they may not be sustainable.
Dividend Sustainability
Based on earnings estimates, Bristol-Myers Squibb will have a dividend payout ratio of 26.50% next year. This indicates that Bristol-Myers Squibb will be able to sustain or increase its dividend.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bristol-Myers Squibb insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,089,050.00 in company stock.
Percentage Held by Insiders
Only 0.09% of the stock of Bristol-Myers Squibb is held by insiders.
Percentage Held by Institutions
73.07% of the stock of Bristol-Myers Squibb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Bristol-Myers Squibb are expected to grow by 7.80% in the coming year, from $7.56 to $8.15 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bristol-Myers Squibb is 27.91, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.35.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bristol-Myers Squibb is 27.91, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 19.27.
Price to Earnings Growth Ratio
Bristol-Myers Squibb has a PEG Ratio of 1.67. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Bristol-Myers Squibb has a P/B Ratio of 4.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

June 3, 2022 | marketbeat.com

Zumiez, Tesla fall; Okta, Calavo Growers rise

Stocks that traded heavily or had substantial price changes Friday: Zumiez, Tesla fall; Okta, Calavo Growers rise

June 28, 2022 | finance.yahoo.com

Dow Jones Rallies As Nike Falls On Weak Sales Guidance

June 28, 2022 | finance.yahoo.com

Dow Jones Futures Climb But Nike Slides On Weak Sales Guidance